Abstract
Voltage-gated sodium ion channels (NaVs) are integral membrane protein complexes responsible for electrical signal conduction in excitable cells. Methods that enable selective labeling of NaVs hold potential value for understanding how channel regulation and post-translational modification are influenced during development and in response to diseases and disorders of the nervous system. We have developed chemical reagents patterned after (+)-saxitoxin (STX)—a potent and reversible inhibitor of multiple NaV isoforms—and affixed with a reactive electrophile and either a biotin cofactor, fluorophore, or ‘click’ functional group for labeling wild-type channels. Our studies reveal enigmatic structural effects of the probes on the potency and efficiency of covalent protein modification. Among the compounds analyzed, a STX-maleimide-coumarin derivative is most effective at irreversibly blocking Na+ conductance when applied to recombinant NaVs and endogenous channels expressed in hippo-campal neurons. Mechanistic analysis supports the conclusion that high-affinity toxin binding is a prerequisite for covalent protein modification. Results from these studies are guiding the development of next-generation tool compounds for selective modification of NaVs expressed in the plasma membranes of cells.
Keywords: sodium channel, covalent inhibitor, saxitoxin, maleimide
Graphical Abstract

Trifunctional chemical probes derived from the potent shellfish poison, (+)-saxitoxin (STX), irreversibly inhibit wild-type voltage-gated sodium channels (NaVs). Saxitoxin derivatives decorated with a maleimide electrophile and either biotin, a fluorescent dye, or biorthogonal-reactive group were synthesized and evaluated using whole-cell, voltage-clamp electrophysiology.
Introduction
The initiation and propagation of action potentials in electrically excitable cells relies on the coordinated actions of ion channels, among which voltage-gate sodium channels are exemplary.[1] These large, heteromeric protein complexes, comprising a pore-forming α-subunit and one or two ß-auxiliary proteins, gate the flow of sodium ions in response to changes in membrane potential.[2] Proper transmission of action potentials requires stringent control of protein spatial distributions, expression levels, and activities, which occurs through transcriptional, translational and post-translational controls. The influence of post-translational protein modifications (PTMs) on channel function is of particular interest to our lab and has motivated the development of tool compounds for selectively capturing membrane-inserted NaVs.[3] Isolation of NaVs by immunoprecipitation with NaV-specific Abs is possible;[4] however, this method does not discriminate between channels inserted in the membrane of cells and those held in intracellular stores. The inability to differentiate between these two limiting ‘populations’ of channels complicates efforts to identify changes in PTMs that occur in rapid response to cellular cues to alter electrical signaling (e.g., acute cellular injury). The lack of specificity of NaV Abs presents further challenges. Accordingly, we envisioned developing NaV-selective, affinity-based ligands that would enable irreversible alkylation of NaVs present exclusively in the outer membrane of cells. Such reagents would be cell-impermeable and engineered for efficient labeling and isolation of membrane NaVs.
Guanidinium toxins, which target the outer vestibule of NaVs to block ion permeation, present an optimal scaffold from which to design NaV-selective tool compounds.[5] These hydrophilic compounds act reversibly with fast on and fast off binding kinetics and have measured IC50 values of ≤ 10 nM against six of nine rat NaV subtypes (i.e., rNaV1.1–1.4, 1.6, 1.7). In our original plan, we conceived of introducing a cysteine (Cys) mutation into one of the four p-loops that form the outer vestibule of the channel. In turn, a Cys-reactive electrophile along with an affinity purification tag (e.g., biotin, ‘click’ functional group) would be conjoined to STX. This type of covalent, chemogenetic pair would, in principle, irreversibly label only the Cys-mutant channel, thus enabling isolation and characterization of a single channel subtype expressly located in the outer membrane.[6] In our efforts to develop such tools, we found that STX-maleimide 1, a first-generation Cys-reactive toxin conjugate, irreversibly inhibited wild-type NaV1.2 and 1.4 (Figure 1).[7] These findings were entirely serendipitous and remain surprising, as there is no obvious candidate Cys group within ~20 Å of the toxin binding site (estimated from cryo-EM structures of NaVs, Figure 1).[8] Herein, we describe results from a comprehensive study to measure the inhibitory behavior of a collection of STX-maleimide conjugates. The aim of this research was to understand how maleimide substitution and ligand concentration alter the efficiency of irreversible block and to determine if ligand binding precedes protein modification. Our findings evidence unexpected structure-activity relationships between different maleimide conjugates and identify a coumarin derivative, 15, that is a potent and effective irreversible inhibitor of NaVs expressed in heterologous cells and present in hippocampal neurons.
Figure 1A.
Saxitoxin and a cysteine-reactive derivative. 1B. Top and side view of NaV1.4 showing STX (green space filling) docked in the outer vestibule. Cys723 and Cy725 are highlighted (yellow space filling). Other cysteine residues are colored in yellow. Domain I = orange; Domain II = red; Domain III = gray; Domain IV = cyan.
Results and Discussion
Design and Synthesis of Substituted Maleimide STX Conjugates
In our original study, maleimide was selected over other Cys-reactive electrophiles such as acetylhalides, acrylamides, and mixed disulfides for its intrinsic reactivity and ease of modification. Design of effective STX-maleimide inhibitors was predicated upon minimizing disruption of toxin binding, assuming that this step would precede the protein alkylation event. Prior studies[7] revealed that C2’-substituted maleimide STX conjugates containing pendant alkyl chains retained irreversible binding activity against wild type-NaVs and was therefore considered an obvious location to introduce a ‘click’ group or affinity tag. Direct incorporation of biotin[9] or a fluorogenic dye[5a,10] was desired as no additional synthetic operations would be required to isolate or visualize toxin-labeled channels. Toxin-maleimide-‘click’ reactive probes, by virtue of the smaller size of the prosthetic groups, might retain higher affinity for binding to the channel, but would necessitate an extra reaction step following protein alkylation.[11]
A synthetic route (Scheme 1) was devised to permit facile attachment of a reporter group to a C2’-substituted maleimide through amide bond formation using N-hydroxysuccinimide (NHS) ester intermediate 6. This chemistry was designed to enable facile preparation of maleimide derivatives to test the effects of the substituent groups on toxin binding and on the rate of protein alkylation.
Scheme 1.
Synthesis of C2’-substituted maleimides. Conditions: (a) O3, PPh3, CH2Cl2, MeOH, –78 °C, 94%; (b) glyoxylic acid, morpholine HCl, dioxane/H2O, 100 °C; (c) allyl bromide, Aliquat 336, NaHCO3, CH2Cl2, H2O, 32% (2 steps); (d) Dess-Martin periodinane, CH2Cl2, 79%; (e) β-alanine, AcOH, 110 °C, 78%; (f) Boc2O, DMAP, t-BuOH, 61%; (g) 5 mol% Pd(PPh3)4, morpholine, THF, MeOH, 94%; (h) N-hydroxysuccinimide, N,N’-dicyclohexylcarbodiimide, CH2Cl2, 88%; (i) i-Pr2NH, DMF, RNH2, 49–88%; (j) CF3CO2H, CH2Cl2; (k) N-hydroxysuccin-imide, EDC, CH2Cl2, 60–72% (2 steps).
Synthesis of C2’-substituted maleimides commenced with ozonolysis of undecylenic acid 2, which proceeded in 94% yield, followed by acidic condensation with glyoxylic acid to form γ-hydroxybutenolide 3 (Scheme 1). Subsequent allylation of the carboxylic acid under Schotten-Baumann conditions, oxidation to the maleic anhydride with Dess-Martin periodinane, and condensation with β-alanine in acetic acid furnished the desired disubstituted maleimide 4. Carboxylic acid protection as the tert-butyl ester and Pd-catalyzed cleavage of allyl ester afforded 5. Interestingly, extended reaction times for the latter reaction resulted in quantitative isomerization of the maleimide to the exocyclic alkene. By limiting reaction times to < 1 h, acid 5 could be exclusively and quantitatively obtained. Activation of 5 as the corresponding NHS ester 6 was followed by coupling to a 1° amine derived with a prosthetic group of choice.
Fully elaborated trifunctional STX conjugates can be prepared through NHS ester coupling reactions to aminoethyl-modified STX.[7] As shown in Figure 2, a diverse set of reporter groups was successfully affixed to the STX maleimide scaffold including biotin (9) and biorthogonal-reactive alkyne (10), ketone[12] (11–12), norbornene[13] (13) and cyclopropene[14] (14) units. In addition to the biotin- and ‘click’-based probes, a 7-(diethylamino)coumarin conjugate (15) was prepared to visualize by fluorescence imaging covalently-labeled NaVs in cells and/or on western blots. The coumarin dye was selected for its optical properties, small size, and neutral charge.[15]
Figure 2.
Preparation of trifunctional STX maleimide conjugates.
Electrophysiological Characterization of Trifunctional STX Maleimide Probes
Whole cell patch-clamp electrophysiology recordings were initially performed against wild-type rat brain channel, rNaV1.2, expressed in Chinese hamster ovary (CHO) cells to assess the inhibitory activity of the trifunctional STX maleimide conjugates. The extent of irreversible current inhibition was determined by comparing the amount of Na+ current (I) recovered after toxin wash-out relative to initial peak current levels (I0) prior to toxin application. Following a six-minute application of a saturating concentration (10 μM) of 15, only partial restoration of initial peak current levels was observed (I/I0 = 43 ± 3%) despite extensive wash-off with toxin-free buffer solution (Figure 3B and 3C). This finding stands in marked contrast to the fully reversible binding behavior of the parent toxin, STX. Decreasing the application time of 15 to one or three minutes resulted in concomitant increase in the extent of current recovery (81 ± 5% and 63 ± 2%, respectively; Figure S2A and S2B), a trend that is consistent with a time-dependent alkylation event and fewer channels being irreversibly labeled. Application of 1 μM 15 for six minutes, however, resulted in almost complete restoration of peak current (I/I0 = 90 ± 1%), indicating that the extent of covalent modification is concentration dependent (Figure S2C). Unfortunately, evaluation of application times beyond six minutes posed a technical challenge due to difficulties with maintaining a high resistance seal on the patched cell for the duration of the experiment. Altogether, these findings suggest that 15 is a competent irreversible inhibitor of NaV1.2, thus validating our probe design.
Figure 3A.
Structure of maleimide (15) and succinimide (16) coumarin STX conjugates. 3B. Current recordings after a 6 min application and wash-off of 10 μM maleimide 15 to CHO cells expressing rNaV1.2. 3C. Representative time course following application and wash-off of 15. 3D. Current recordings after a 6 min application and wash-off of 10 μM succinimide 16. 3E. Representative time course following application and wash-off of 16. Average current recovery upon wash out was 43 ± 3% for 15 compared to 95 ± 10% for 16.
Succinimide coumarin derivative 16, a saturated analog of 15 incapable of protein alkylation, was employed as a control compound to confirm that irreversible current block of rNaV1.2 is dependent on the electrophilic maleimide. As with 15, incubating 10 μM 16 with cells expressing rNaV1.2 resulted in complete block of sodium current (Figure 3D and 3E). However, in stark contrast to 15, peak current (I/I0 = 95 ± 10%) was restored upon toxin wash-out, behavior mirroring that of STX. The divergent activity between maleimide 15 and succinimide 16 conjugates strongly implicates protein alkylation by the maleimide electrophile as the mechanism for irreversible current block of rNaV1.2.
We evaluated biotin 9, α-ketoamide 12, norbornene 13, and cyclopropene 14 conjugates to determine if and to what extent the choice of prosthetic group altered the extent of irreversible current block.[7] Surprisingly, these derivatives showed markedly different propensities to irreversibly inhibit rNaV1.2 compared to 15. Incubation of biotin 9 (10 μM, 6 min) resulted in full restoration of peak current following wash-off, indicating that no reaction with the channel occurred. ‘Click’-based probes, 12 and 13, fared better than 9, but were notably less efficient than 15 (Figure S3A–C) and cyclopropene 14 demonstrated similar binding behavior to its succinimide counterpart. These results underscore the challenges in designing, optimizing, and advancing effective trifunctional covalent inhibitors of wild-type NaVs.
IC50 values were measured for trifunctional succinimide analogs to gauge the relative affinity of these compounds for NaV1.2 and to potentially gain insight into the disparate results between the maleimide conjugates tested (Figure S4). An IC50 value of 79 ± 8 nM was determined for coumarin 16 against rNaV1.2, only a two-fold decrease in binding affinity relative to the unsubstituted STX-succinimide conjugate (IC50 = 38 ± 5 nM).[7] Concentration-response measurements for succinimide derivatives 17–19 yielded IC50 values of 257 ± 9 nM, 126 ± 15 nM, and 105 ± 6 nM, respectively, and 324 ± 48 nM for the reversible maleimide, 9. Collectively, these results reveal that structural changes to both the linker and reporter groups alter rather substantially ligand potency and the rate of wild-type rNaV1.2 alkylation.
We performed additional characterization of coumarin 15, the most effective irreversible inhibitor of rNaV1.2, against other NaV isoforms and NaVs expressed in primary cells. Inhibitory constants for succinimide 16 (Figure S5A) were measured using rNaV1.4 (IC50 = 105 ± 14 nM, CHO cells) and rat embryonic hippocampal neurons (IC50 = 99 ± 6 nM), the latter of which endogenously express multiple STX-sensitive NaV isoforms in complex with β subunits.[16] As expected, wash-off of 16 was entirely reversible. These data show marginal differences in the binding affinities and kinetics for 16 towards STX-sensitive isoforms and cell types. With 15, irreversible inhibition was confirmed (10 μM, 6 min incubation time) against both rNaV1.4 (I/I0 = 50 ± 4%, Figure S5B) and rat embryonic hippocampal neurons (I/I0 = 44 ± 7%, Figure S5C). The magnitude of irreversible block is equivalent to that measured with rNaV1.2 and demonstrates that this phenomenon is neither cell-specific nor noticeably affected by the presence of β subunits.
Investigating the Mechanism of Irreversible NaV Inhibition
We conducted a series of experiments to further understand the mechanism of covalent inhibition of wild-type NaVs by coumarin 15. Electrophysiology experiments using 20, a maleimide coumarin conjugate derived from β-saxitoxinol, a micromolar inhibitor of STX-sensitive channels, support the view that high-affinity toxin binding to NaV is a prerequisite for irreversible current block (Figure 4A). The IC50 of β-saxitoxinol is ~10,000-fold less than that of STX.[17] Accordingly, a six-minute application of 10 μM 20 to CHO cells expressing rNaV1.2 afforded only partial current block and complete current restoration (I/I0 = 103 ± 5%) following wash-out (Figure 4B). That 20 bears a reactive maleimide moiety and does not irreversibly alter peak current suggests that protein alkylation by 15 is mediated through a specific interaction between toxin conjugate and channel.
Figure 4A.
Structure of β-saxitoxinol maleimide coumarin 20. 4B. Representative wash-off time course of 10 μM 20 against rNaV1.2. 4C. Representative wash-off time course of 10 μM 15 against rNaV1.4 E758D. Average current recovery following wash-off was 81 ± 6% (B), and 103 ± 4% (C).
We employed protein mutagenesis to provide additional support that high affinity toxin binding to the channel pore is required for protein alkylation. In STX-resistant clams, E758D (rNaV1.4 numbering) is a naturally occurring amino acid variation in the outer vestibule of NaVs that significantly destabilizes toxin binding (IC50 = 9.8 ± 0.18 μM).[18,19] Accordingly, the binding behavior of coumarin 15 was evaluated against the rNaV1.4 E758D mutant. Application of 10 μM 15 to cells expressing rNaV1.4 E758D reduced peak current by ~40%, consistent with the destabilizing effect of this mutation on toxin binding. Toxin wash-off, however, resulted in complete restoration of I0 (I/I0 = 103 ± 4%, Figure 4C). These observations argue that protein alkylation is dependent on specific and potent toxin binding within the outer channel pore.
The potency of STX towards NaVs is influenced, albeit modestly, by the frequency of the electrophysiology stimulation protocol (i.e., use-dependence).[20] As shown in Figure 5A, use-dependent effects for STX against rNaV1.2 manifest as differences in IC50 values, 1.2 ± 0.1 nM and 2.9 ± 0.1 nM, for recordings at high (f =1/2 Hz) versus low (f = 1/30 Hz) frequency, respectively.[20a] We examined use-dependent binding with succinimide 16 to determine the extent to which, if any, irreversible block of current was altered by the stimulus protocol. Like STX, 16, shows a modest (< 3-fold) change in IC50 at lower stimulating frequencies (79 ± 8 nM vs 214 ± 52 nM, respectively).
Figure 5A.
Use-dependent concentration-response measurements of STX and succinimide 16 against rNaV1.2 at high (f = 1/2 Hz) and low (f = 1/30 Hz) frequency stimulation. 5B. Representative time course experiment demonstrating use-dependent irreversible inhibition of rNaV1.2 with 10 μM 15.
To investigate the frequency dependence of irreversible inhibition, time course wash-off experiments were performed with coumarin 15 (Figure 5B). Following application of 15 (10 μM, 6 min) at low frequency stimulus (f = 1/30 Hz), wash-off with toxin-free buffer solution led to the recovery of 66 ± 8% of initial current. This value compares to I/I0 = 43 ± 3%, which was obtained for 15 using a high-frequency stimulation protocol. These findings provide additional support that tight binding of toxin to its receptor is necessary for efficient protein alkylation.
Efforts to identify the protein residue(s) that undergoes reaction with the maleimide electrophile have yielded inconclusive results. Although prior work to implicate a Cys as the nucleophilic residue were unsuccessful,[7] we revisited this possibility following a report that μOξ-conotoxin GVIIJ, a peptidic cone snail toxin, formed a disulfide bond with a Cys residue in the receptor site of wild-type rNaV1.2.[21] This conserved residue (C723, rNaV1.4 numbering) and a neighboring Cys (C725) were each successfully mutated to leucine and alanine in rNaV1.4, respectively (see Figure 1). When transfected in CHO cells, these mutant channels produced macroscopic current levels sufficient in magnitude for electrophysiological evaluation of toxin binding. Application of parent maleimide 1 (5 μM, 6 min) resulted in the irreversible inhibition of rNaV1.4 C723L (I/I0 = 19 ± 2%) and C725A (I/I0 = 17 ± 9%) mutant channels at levels that mirror results with wild-type rNaV1.4.[7a] Based on these experiments, we conclude that C723 and C725 do not engage the maleimide. At this time, we cannot rule out the possibility that a nucleophilic residue(s) other than Cys is covalently modified.
Conclusion
We prepared seven unique trifunctional STX-maleimide conjugates and performed whole-cell electrophysiology experiments to characterize the binding activity and efficacy of these compounds as covalent modifiers of wild-type NaV isoforms. Among this collection of reagents, a coumarin derivative was identified as optimal in terms of potency and efficiency of irreversible channel block. Mechanistic studies with succinimide-based analogues and mutant sodium channels establish that high-affinity toxin binding to the channel is a prerequisite for successful protein modification. Protein mutagenesis experiments aimed at identifying the nucleophilic amino acid residue(s) that engages the maleimide electrophile were, however, inconclusive. Efforts to further improve these tool compounds for affinity labeling and proteomics analyses of NaVs are ongoing.
Supplementary Material
Acknowledgements
We are grateful to the National Institutes of Health R01 GM117263-05 for support of this work.
Footnotes
Supporting Information
Experimental protocols and characterization data for all new compounds. Electrophysiology recording protocols and voltage-clamp data. The authors have cited additional references within the Supporting Information.[22–27]
Supporting information for this article is given via a link at the end of the document.
References
- [1] a).Loussouarn G, Tarek M, Front. Pharmacol 2021, 12, 768153. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Levin M, Mol. Biol. Cell 2014, 25, 3835–3850; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Ruiz M. de Lera, Kraus RL, J. Med. Chem 2015, 58, 7093–7118; [DOI] [PubMed] [Google Scholar]; d) Hille B, Ion Channels of Excitable Membranes, 3rd Ed., Sinauer Associates, Sunderland, Massachusetts, 2001. [Google Scholar]
- [2] a).Ahern CA, Payandeh J, Bosmans F, Chanda B, J. Gen. Physiol 2016, 147, 1–24; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Catterall WA, J. Physiol 2012, 590, 2577–2589; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Goldin AL, Annu. Rev. Physiol 2001, 63, 871–894. [DOI] [PubMed] [Google Scholar]
- [3] a).Pei Z, Pan Y, Cummins TR in Voltage-gated Sodium Channels: Structure, Function and Channelopathies. Handbook of Experimental Pharmacology, Vol. 246 (Ed.: Chahine M), Springer, Cham, 2017; [Google Scholar]; b) Onwuli DO, Beltran-Alvarez P, Amino Acids 2016, 48, 641–651; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Laedermann CJ, Abriel H, Decosterd I, Front. Pharmacol 2015, 6, 263. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Curran J, Mohler PJ, Ann. Rev. Physiol 2015, 77, 505–524; [DOI] [PubMed] [Google Scholar]; e) Scheuer T, Semin. Cell Dev. Biol 2011, 22, 160–165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].For representative examples, see: a)Arribas-Blázquez M, Piniella D, Olivos-Oré LA, Bartolomé-Martin D, Leite C, Giménez C, Artalejo AR, Zafra F, Neuropharmacol. 2021, 197, 108745; [DOI] [PubMed] [Google Scholar]; b) Marionneau C, Abriel H, J. Mol. Cell. Cardiol 2015, 82, 36–47; [DOI] [PubMed] [Google Scholar]; c) Berendt FJ, Park K-S, Trimmer JS, J. Proteome Res 2010, 9, 1976–1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5] a).Elleman AV, Du Bois J, ChemBioChem 2022, 23, e202100625; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Thottumkara AP, Parsons WH, Du Bois J, Angew. Chem. Int. Ed 2014, 53, 5760–5784. [DOI] [PubMed] [Google Scholar]
- [6] a).Miura Y, Senoo A, Doura T, Kiyonaka S, RSC Chem. Biol 2022, 3, 269–287; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Atasoy D, Sternson SM, Physiol. Rev 2018, 98, 391–418. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [7] a).Parsons WH, Du Bois J, J. Am. Chem. Soc 2013, 135, 10582–10585; [DOI] [PubMed] [Google Scholar]; b) Andresen BM, Du Bois J, J. Am. Chem. Soc 2009, 131, 12524–12525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8] a).Pan X, Li Z, Zhou Q, Shen H, Wu K, Huang X, Chen J, Zhang J, Zhu X, Lei J, Xiong W, Gong H, Xiao B, Yan N, Science 2018, 362, eaau2486; [DOI] [PubMed] [Google Scholar]; b) Pan X, Li Z, Huang X, Huang G, Gao S, Shen H, Liu L, Lei J, Yan N, Science 2019, 363, 1309–1313. [DOI] [PubMed] [Google Scholar]; Also, see: Jiang D, Zhang J, Xia Z Front. Pharmacol 2022, 13, 908867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9] a).Trippier CP, ChemMedChem 2013, 8, 190–203; [DOI] [PubMed] [Google Scholar]; b) Robillot C, Kineavy D, Burnell J, Llewellyn LE, Toxicon 2009, 53, 460–465. [DOI] [PubMed] [Google Scholar]
- [10].Ondrus AE, Lee H.-l. D., Iwanaga S, Parsons WH, Andresen BM, Moerner WE, Du Bois J, Chem. Biol 2012, 19, 902–912. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11] a).Bird RE, Lemmel SA, Yu X, Zhou QA, Bioconjug. Chem 2021, 32, 2457–2479; [DOI] [PubMed] [Google Scholar]; b) Sletten EM, Bertozzi CR, Angew. Chem. Int. Ed 2009, 48, 6974–6998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Isolated as a 3:2 mixture of ketone and ketone hydrate. For an example of fluorescent labeling using α-ketoamide electrophiles, see: Bindman NA, van der Donk WA, J. Am. Chem. Soc 2013, 135, 10362–10371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13] a).Vrabel M, Kölle P, Brunner KM, Gattner MJ, López Carrillo V, de Vivie-Riedle R, Carell T, Chem. Eur. J 2013, 19, 13309–13312; [DOI] [PubMed] [Google Scholar]; b) Han H-S, Devaraj NK, Lee J, Hilderbrand SA, Weissleder R, Bawendi MG, J. Am. Chem. Soc 2010, 132, 7838–7839. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14] a).Ravasco JMJM, Monteiro CM, Trinidade AF, Org. Chem. Front 2017, 4, 1167–1198; [Google Scholar]; b) Patterson DM, Nazarova LA, Xie B, Kamber DN, Prescher JA, J. Am. Chem. Soc 2012, 134, 18638–18643; [DOI] [PubMed] [Google Scholar]; c) Yang J, Šečkutė J, Cole CM, Devaraj NK, Angew. Chem. Int. Ed 2012, 51, 7476–7479. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15] a).Cao D, Liu Z, Verwilst P, Koo S, Jangili P, Kim JS, Lin W, Chem. Rev 2019, 119, 10403–10519; [DOI] [PubMed] [Google Scholar]; b) Sun X-Y, Liu T, Sun J, Wang X-J, RSC Adv. 2020, 10, 10826–10847; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Jin X, Uttamapinant C, Ting AY, ChemBioChem 2011, 12, 65–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16] a).Kim DY, Kovacs DM, Methods Mol. Biol 2011, 793, 351–361; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Mechaly I, Scamps F, Chabbert C, Sans A, Valmier J, Neuroscience 2005, 130, 389–396. [DOI] [PubMed] [Google Scholar]
- [17] a).Andresen BM, PhD. thesis, Stanford University (USA), 2010; [Google Scholar]; b) Relative toxicity measurements in mice indicate STX is at least ~1000-fold more toxic than β-saxitoxinol, see: Koehn FE, Ghazarossian VE, Schantz EJ, Schnoes HK, Strong FM, Bioorg. Chem 1981, 10, 412–428. [Google Scholar]
- [18].Bricelj VM, Connell L, Konoki K, MacQuarrie SP, Scheuer T, Catterall WA, Trainer VL, Nature 2005, 434, 763–767. [DOI] [PubMed] [Google Scholar]
- [19].Thomas-Tran R, Du Bois J, Proc. Natl. Acad. Sci. U.S.A 2016, 113, 5856–5861. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [20] a).Huang C-J, Schild L, Moczydlowski EG, J. Gen. Physiol 2012, 140, 435–454; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Cervenka R, Zarrabi T, Lukacs P, Todt H, Mar. Drugs 2010, 8, 1373–1393; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Salgado VL, Yeh JZ, Narahashi T, Ann. NY Acad. Sci 1986, 479, 84–95. [DOI] [PubMed] [Google Scholar]
- [21].Gajewiak J, Azam L, Imperial J, Walewska A, Green BR, Bandyopadhyay PK, Raghuraman S, Ueberheide B, Bern M, Zhou HM, Minassian NA, Hagan RH, Flinspach M, Liu Y, Bulaj G, Wickenden AD, Olivera BM, Yoshikami D, Zhang M, Proc. Natl. Acad. Sci. U.S.A 2014, 111, 2758–2763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [22].Bennett E, Urcan MS, Tinkle SS, Koszowki AG, Levinson SR, J. Gen. Physiol 1997, 109, 327–343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [23].Xie W, Zhang K, Cui B, Integr. Biol 2012, 4, 953–960. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [24].Moran O, Piccolo A, Conti F, Biophys. J 2003, 84, 2999–3006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [25].Parsons WH, PhD. thesis, Stanford University (USA), 2013. [Google Scholar]
- [26].Pontrello JK, Allen MJ, Underbakke ES, Kiessling LL, J. Am. Chem. Soc 2005, 127, 14536–14537. [DOI] [PubMed] [Google Scholar]
- [27].Watanabe R, Suzuki T, Oshima Y, Toxicon 2010, 56, 589–595. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.






